- Home
- NERV vs GNLN Comparison
NERV vs GNLN Comparison
Compare NERV & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- GNLN
- Stock Information
- Founded
- NERV 2007
- GNLN 2005
- Country
- NERV United States
- GNLN United States
- Employees
- NERV N/A
- GNLN N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- GNLN Durable Goods
- Sector
- NERV Health Care
- GNLN Consumer Discretionary
- Exchange
- NERV Nasdaq
- GNLN Nasdaq
- Market Cap
- NERV 14.6M
- GNLN 12.9M
- IPO Year
- NERV 2014
- GNLN 2019
- Fundamental
- Price
- NERV $3.78
- GNLN $3.26
- Analyst Decision
- NERV Hold
- GNLN
- Analyst Count
- NERV 1
- GNLN 0
- Target Price
- NERV $4.00
- GNLN N/A
- AVG Volume (30 Days)
- NERV 101.0K
- GNLN 39.6K
- Earning Date
- NERV 11-05-2025
- GNLN 11-14-2025
- Dividend Yield
- NERV N/A
- GNLN N/A
- EPS Growth
- NERV N/A
- GNLN N/A
- EPS
- NERV N/A
- GNLN N/A
- Revenue
- NERV N/A
- GNLN $4,653,000.00
- Revenue This Year
- NERV N/A
- GNLN $1,541.21
- Revenue Next Year
- NERV N/A
- GNLN N/A
- P/E Ratio
- NERV N/A
- GNLN N/A
- Revenue Growth
- NERV N/A
- GNLN N/A
- 52 Week Low
- NERV $1.15
- GNLN $2.68
- 52 Week High
- NERV $12.46
- GNLN $1,537.54
- Technical
- Relative Strength Index (RSI)
- NERV 49.13
- GNLN 52.51
- Support Level
- NERV $3.76
- GNLN $2.79
- Resistance Level
- NERV $4.42
- GNLN $3.48
- Average True Range (ATR)
- NERV 0.32
- GNLN 0.24
- MACD
- NERV -0.09
- GNLN 0.07
- Stochastic Oscillator
- NERV 25.93
- GNLN 78.75
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.